At 2025 ASCO Annual Meeting, Analysis Group to Present New Outcomes

Event:2025 ASCO Annual Meeting
Dates: May 30–June 3, 2025
Host: American Society of Clinical Oncology (ASCO)
Location: Chicago, Il/Online

Members of Analysis Group’s HEOR, Epidemiology & Market Access practice will present seven posters at the 2025 ASCO Annual Meeting. The program will feature a range of educational and scientific sessions on cancer research, treatment, and patient care.

Analysis Group poster presentations include:

Quality Care/Health Services Research – May 31, 2025, 1:30 p.m.–4:30 p.m. CT

  • “Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): A global discrete-choice experiment (DCE) study,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Todor Totev, Senior Research Professional Lilian Diaz, Research Professional Fengyi Jiang, and Associate Yan Meng – in collaboration with researchers from The Follicular Lymphoma Foundation, and BeOne Medicines. Funding for this study was provided by BeOne Medicines.

Hematologic Malignancies – June 1, 2025, 9:00 a.m.–12:00 p.m. CT

  • “Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM),” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou, Manager Mirko Fillbrunn, and Senior Analysts Matthew Mattera and Hongjue Wang – in collaboration with researchers from the Icahn School of Medicine at Mount Sinai, The University of Texas MD Anderson Cancer Center, Karmanos Cancer Institute, the Wayne State University School of Medicine, the University of Miami Health System, Regeneron Pharmaceuticals, and The Ohio State University Comprehensive Cancer Center. Funding for this study was provided by Regeneron Pharmaceuticals.
  • “Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia,” coauthored by an Analysis Group team – including Manager Rebecca Burne – in collaboration with researchers from Rabin Medical Center, Weill Cornell Medicine, Dana-Farber Cancer Institute, the University of North Carolina at Chapel Hill, Duke University School of Medicine, the Medical College of Wisconsin, the University of Alabama, Moffitt Cancer Center, Tel Aviv Sourasky Medical Center, the University of Colorado School of Medicine, the University of Pennsylvania, Montefiore Einstein Comprehensive Cancer Center, the Hebrew University of Jerusalem, Sunnybrook Odette Cancer Centre, Scripps Cancer Center, Rambam Health Care Campus, AbbVie, Genentech, Memorial Sloan Kettering Cancer Center, and Medstar Georgetown University Hospital. Funding for this study was provided by AbbVie and Genentech.

Melanoma/Skin Cancers – June 1, 2025, 9:00 a.m.–12:00 p.m. CT

  • “Real-world comparison of survival with nivolumab (NIVO) + relatlimab (RELA) vs NIVO + ipilimumab (IPI) in advanced melanoma,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou, Manager Yiqiao Xin, Associate Yuehan Zhang, Senior Analyst Matthew Mattera, and Analyst Loren Ormenaj – in collaboration with researchers from Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Inova Schar Cancer Institute, Bristol Myers Squibb, and the HonorHealth Research Institute. Funding for this study was provided by Bristol Myers Squibb.
  • “Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year follow-up data,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou, Associate Hannah Kim, and Senior Analyst Dana Christensen – in collaboration with researchers from University of Essen and the German Cancer Consortium, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Istituto Nazionale Tumori IRCCS Fondazione Pascale, The Royal Marsden NHS Foundation Trust, the University of Michigan, Aix-Marseille University, Bristol Myers Squibb, and Melanoma Institute Australia. Funding for this study was provided by Bristol Myers Squibb.

Genitourinary Cancer – June 2, 2025, 9:00 a.m.–12:00 p.m. CT

  • “Assessing real-world recurrence in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guérin (BCG) in the United States through a recurrence algorithm: A SEER-Medicare study,” coauthored by an Analysis Group team – including Vice Presidents Wei Gao and Yan Song, Manager Honghao Fang, Associate Jiayang Li, and Senior Analyst Pangsibo Shen – in collaboration with researchers from The University of Texas Southwestern Medical Center and Merck. Funding for this study was provided by Merck.
  • “How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data,” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Vice President Wei Gao, and Senior Analysts Grace Chen and Jingyi Chen – in collaboration with researchers from Cedars-Sinai Medical Center, Durham VA Medical Center, Astellas Pharma, and Pfizer. Funding for this study was provided by Astellas Pharma and Pfizer.

In addition, the following studies have been accepted for online publication:

  • “Does race predict adherence to relugolix among patients with prostate cancer? A Veterans Health Administration data analysis,” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Vice President Wei Gao, Associate Tracy Guo, and Senior Analyst Grace Chen – in collaboration with researchers from Cedars-Sinai Medical Center, Durham VA Medical Center, Pfizer, Sumitomo Pharma, and the University of California San Diego. Funding for this study was provided by Pfizer and Sumitomo Pharma.

  • “Real-world treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitor (ARPI) or docetaxel,” coauthored by an Analysis Group team – including Vice President Jenny Zhou, Manager Xiaoyu Nie, and Associate Travis Wang – in collaboration with researchers from Huntsman Cancer Institute at the University of Utah, City of Hope, and Exelixis. Funding for this study was provided by Exelixis.

View additional information

Associated People